Journals / İstanbul Tıp Dergisi / 2012 / Cilt: 13 - Sayı: 4

Analysis of 47 patients with triple negative (er, pgr, her2) breast cancer

Üçlü (er, pgr, her2) negatif 47 meme kanserli hastanın değerlendirilmesi

Pages
166–168
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Current medical practice focuses on therapies useful for ER, PGR, HER2 positive tumors thus new treatment modalities targeting triple negative breast cancer are needed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Breast cancer is the most common cancer in women.
📊
Key Findings & Data:In current medical practice ER, PGR, HER2 levels have been important prognostic factors changing the outcome and the treatment modalities.
💡
Conclusion & Impact:Current medical practice focuses on therapies useful for ER, PGR, HER2 positive tumors thus new treatment modalities targeting triple negative breast cancer are needed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Breast cancer is the most common cancer in women. Breast cancer responds variable depending on morphological, clinical, hormonal receptor level differenc- es. In current medical practice ER, PGR, HER2 levels have been important prognostic factors changing the outcome and the treatment modalities. Methods: Women operated for breast cancer in our clin- ic were analysed. 47 cases with negative prognostic and predictive proteins (ER, PGR, HER2) were included in the study. Median follow-up was 36 months and recurrences were evaluated. Results: 23 (49%) patients were younger than 50, 24 (51%) were older than 50. Most of the cases were invasive ductal carcinoma (78%), second most common was metaplastic carcinoma followed by invasive ductal carcinoma show- ing myoepithelial differentiation. 36% of the tumors were nuclear grade II, 64% were nuclear grade III. 36% of the tumors had angiolymphatic invasion. Average tumor size was 3.6 cm. 14% of the tumors were T1 (0-2 cm), 86% were T2 (2-5 cm), 10% were T3 (larger than 5 cm). There was no lymph node metastasis in 41.2% of the patients. 58% had lymph node metastasis. Modified radical mastectomy was performed in 68%, 32% had lumpectomy. 92% underwent chemotherapy and radiotherapy. During the 36 month follow up recurrence occured in 17 (36%) cases. 7 were local (41%) and 10 (59%) were distant recurrences. Conclusion: Triple negative breast cancers have bad prognosis with high histopathological grade, high risk of invasion and short outcome. Current medical practice focuses on therapies useful for ER, PGR, HER2 positive tumors thus new treatment modalities targeting triple negative breast cancer are needed.

Özet

AMAÇ: Meme kanseri kadınlarda en sık görülen kanser olup, morfolojik, klinik, hormon reseptör düzeyi, tedaviye yanıtlarına göre farklı özellikleri olan tümörlerdir. Günümüzde bu tümörlere yapılan medikal tedavilerde ER, PGR, HER 2 düzeyleri önemli ölçüde yol gösterici ve sağkalımı etkileyici prognostik faktörlerdir.YÖNTEMLER: Kliniğimizde meme kanseri nedeniyle opere edilen hastalarda yapılan tarama sonucu her üç prognostik ve prediktif proteini (ER, PGR, HER 2) negatif olan 47 olgu değerlendirilmeye alındı. Ortanca 36 aylık takip ortaya konuldu ve yinelemeler değerlendirildi.BULGULAR: 47 hastanın 23'ü (%49'u) 50 yaş altı, 24 (%51'i) 50 yaş üstüdür. Olguların çoğu invazif duktal karsinom (%78) olup ikinci sıklıkla metaplastik karsinom ve myoepitelyal diferansiyon gösteren invaziv duktal karsinomdur. %36'sı nükleer grade II, %64'ü nükleer grade III idi. %36'sında anjiolenfatik invazyon mevcuttu. Olguların ortalama tümör çapı 3,6 cm olup;%14'ü T1 (0-2cm), %86'sı T2 (2-5cm), %10'u T3 (5cm üzeriydi). Olguların %41,2'sinde lenf bezi metastazı saptanmadı. %58'sinde lenf bezi metastazı mevcuttu. Olguların %68'ine modifiye radikal mastektomi, %32'sine meme koruyucu cerrahi yapıldı. Olguların %92'sine radyoterapi ve kemoterapi yapılmıştır. 36 aylık takipte 17 (%36) olguda yineleme meydana geldi. Yinelemeleri 7'si lokal(%41), 10'u uzak yineleme (%59) idi.SONUÇ: Üçlü negatif tümörler kötü prognozlu yüksek histolojik grade'e sahip, invazyon riski yüksek, sağkalımı kötü olan tümörlerdir. ER, PGR, HER2'yi hedefleyen günümüz tedavilerinden yararlanamayan bu grup hastaların yeni yaklaşımlara ihtiyaçları vardır.

🔖

Cite This Article

ÇELİK, G., AKSOY, Ş., BAHADIR, F., GÜCİN, Z., ÖZORAN, E., GÜNEŞ, M. E., TRABULUS, F. D., AREN, A. (2022). Analysis of 47 patients with triple negative (er, pgr, her2) breast cancer. İstanbul Tıp Dergisi, Cilt: 13 - Sayı: 4, 166–168. https://ajindex.com/articles/552506

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Çiçin İ. Hormon reseptörü negatif ve HER-2 negatif meme kanserli hastalarla hormon reseptörü negatif ve HER-2 pozitif meme kanserli hastaların demografik, patolojik ve klinik özelliklerinin karşılaştırılması. [Yan Dal Uzmanlık Tezi] Edirne: 2008
  2. Ravdin PM, Cronin KA, Howlader N, et al. The de- crease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-4
  3. Rakha EA, El-Sayed ME, Green AR, et al. Prognos- tic markers in triple-negative breast cancer. Cancer 2007;109:25-32
  4. Filho SJ, Path MRC. Basal like brast cancers: From pathology to Mouse models and beyond. Breast Can- cer Research Centre. London UK
  5. Dairkee SH, Ljung BM, Smith H, et al. Immunolocal- ization of a human basal epithelium specific keratin in benign and malignant breast disease. Breast Cancer Res Treat 1987;10:11-20
  6. Hannemann J, Kristel P, van Tinteren H, et al. Mo- lecular subtypes of breast cancer and amplifica- tion of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 2006;95:1334-41
  7. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235-44
  8. Brenton JD, Carey LA, Ahmed AA, et al. Molecu- lar classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350-60
  9. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of oestrogen recep- tor negative invasive breast carcinoma. Mod Pathol 2004;17:646-52
  10. Bahadır F. Östrojen reseptörü negatif invaziv meme karsinomlarının morfolojik immunofenotipik analizi ve yeni fonksiyonel meme karsinomu sınıflamasındaki yeri. [Uzmanlık Tezi]